REG - MyHealthChecked PLC - Half-year Report
26/09/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250926:nRSZ9005Aa&default-theme=true
RNS Number : 9005A MyHealthChecked PLC 26 September 2025
MyHealthChecked PLC
("MyHealthChecked", "MHC" the "Group" or the "Company")
Half-Year Report
MyHealthChecked PLC, the consumer home-testing healthcare company, announces
its unaudited half-year report for the six months ended 30 June 2025.
Financial highlights
· Revenue of £0.5m (H1 2024: £0.9m; FY 2024: £3.6m) with wellness
portfolio up c60% from H1 2024
· Adjusted EBITDA loss £1,230,000 (H1 2024: £1,199,000; FY 2024:
£1,927,000)
· Cash balances of £5.06m (H1 2024: £6.05m; FY 2024: £5.47m)
Commercial and operational highlights
· The Company signed a partnership agreement with Patients Know Best
("PKB") to enable customers using at-home blood and DNA tests from MHC to
access their laboratory test results via the NHS App
· MHC became the exclusive supplier of PocDoc into Boots, which was
added to the boots.com range in April 2025 and launched in over 830 stores
· Signed agreement with Boots for the supply of a range of lateral flow
self-tests and laboratory tests under the Boots' Own Brand ("OB") label
· End-customer purchases of wellness tests performed well- 45% volume
increase year-on-year
· Phlebotomy kits registered in the UK and EU and will be launched at
retail at the earliest opportunity
Penny McCormick, Chief Executive Officer of MyHealthChecked PLC, said:
"As a Board we believe in the positive long-term growth potential for our
wellness product range, but acknowledge that the category is still in its
infancy and that awareness amongst potential end-users is currently limited.
"As an organisation with deep retail product knowledge, we have built a number
of partnerships to support our retail engagement in the home-testing market.
In particular, with Boots we are working with a trusted established retail
organisation, with both digital reach and a bricks and mortar footprint, and
we believe this is key to unlocking revenue potential in the UK market. With
several promotional campaigns being launched by Boots in the coming months we
expect to see demand increase as the range beds in, and increased product
visibility as more shelf space is dedicated to the range in store. This, along
with our other commercial partnerships, gives us confidence that we will
continue to deliver year-on-year growth in end-user sales for our Wellness
portfolio."
MyHealthChecked PLC www.myhealthcheckedplc.com (http://www.myhealthcheckedplc.com)
Adam Reynolds, Chairman via Walbrook PR
Penny McCormick, Chief Executive Officer
SPARK Advisory Partners Limited (NOMAD) Tel: +44 (0)20 3368 3550
Neil Baldwin / Jade Bayat
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
David Poutney / Nicholas Chambers
Walbrook PR Ltd (Media & IR) Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
(mailto:myhealthcheckedplc@walbrookpr.com)
Paul McManus / Alice Woodings Mob: +44(0)7980 541 893 / +44(0)7407 804 654
About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com) )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests.
MyHealthChecked (http://www.myhealthchecked.com) is the umbrella brand of a
range of at-home rapid tests, as well as DNA, RNA and blood sample collection
kits which have been created to support customers on their journeys to
wellness. The tests are lateral-flow self-tests, whilst the sample collection
kits enable the collection of blood, urine, nasal or mouth swab samples that
are analysed in partner laboratories for a range of biomarkers. The tests are
made available through MHC online and through retail partners in-store and
online.
The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare and proactive wellness in the growing at home testing kit market,
with a focus on accessibility at the right price, led by UK-based experts.
CHAIRMAN AND CEO JOINT STATEMENT
During the first half of 2025, the Board has been encouraged by the
year-on-year growth in end-user sales for our Wellness portfolio which has now
bedded-in at retailer-level. Internally, we have invested in the integration
with Patients Know Best ("PKB") and have delivered to Boots UK Limited
("Boots") a full "Own Brand" testing portfolio the launch of which marks
Boots' arrival as a key player in the home-testing space. Compliance has
continued to drive the culture within our organisation as we cement our
reputation as a solid, trusted and reliable partner with established expertise
within the retailer home-testing space.
Business Review
Boots Own Brand
During the period under review we have continued to prioritise our
collaboration with Boots, a partnership that enables MHC to play a pivotal
role in the transformation of accessible healthcare, at a time of significant
shifts in consumer demand and purchasing behaviour. Since the launch of COVID
testing in May 2021, and the introduction of a wellness testing portfolio in
May 2023, and with preparations underway for the rollout of phlebotomy testing
services, the Company has executed a phased testing strategy with Boots that
is expected to provide scalable, recurring revenue streams and establish a
foundation for continued growth within the evolving retail healthcare sector.
As previously reported on 17 July 2025 the Company signed an agreement with
Boots for the supply of a range of lateral flow self-tests and laboratory
tests under the Boots' Own Brand ("OB") label which comprised eight blood
tests, one DNA test, and four lateral flow self-tests. This was a primary
project for Boots as they looked to broaden their health tests portfolio with
differentiated, own-brand products; it has also been a major development
programme for MHC, and one that was delivered successfully, and on-time, for
its launch on 4 August 2025. Through market testing in 2024, we identified
that the positioning of Boots' OB as an alternative within the wellness
category significantly uplifted demand for the category overall, and
demonstrated, within this early phase of testing, that customer choice is
important. As there will be several promotional campaigns by Boots in the
coming months we expect to see demand increase as the range beds in, and
visibility increases across the category due to increased space on shelf
fixtures in selected stores.
MHC Wellness Portfolio
Sales of the MHC wellness range increased significantly in 2025 over the
comparable period in the prior year with unit sales to end users increasing by
45%, with the most significant growth being in the higher value blood tests
where sales volumes increased by 72% versus the same period last year. We also
participated in several retail promotional programmes some of which focused
purely on testing as well as others that expanded promotional activity into
the nutritional supplement category. These promotions have provided valuable
feedback on customer behaviours and, as a consequence, we are becoming better
informed about where the opportunities for future growth in retail lie. As
reported previously on 14 January 2025 our phlebotomy test kits have been
registered in the UK and EU, and will be launched at retail at the earliest
opportunity, which will be partner dependent.
COVID sales
As our key customer entered 2025 with high stock levels of COVID Lateral Flow
Tests ("LFTs") sales of COVID LFTs during H1 amounted to £nil (six months
ended 30 June 2024: £572,000; year ended 31 December 2024: £2,881,000). As
expected, with the pandemic long behind us, the demand for COVID tests
continues to fall year-on-year with unit sales to end users in H1 running at
approximately 32% of the comparable period in the prior year. However,
although it is difficult to forecast sales with any degree of certainty with
the current level of demand, and the unpredictable winter season still ahead,
we will have some COVID revenue in H2.
Patients Know Best
As previously reported on 23 July 2025 the Company signed a partnership
agreement with Patients Know Best ("PKB") to enable customers using at-home
blood and DNA tests from MHC to access their laboratory test results via the
NHS App. The efforts of our digital team this year have therefore focused on
this integration as it will build long-term customer loyalty through the
seamless, secure integration of test results into the national health data
systems.
Our goals when we defined MHC's testing strategy were firstly, to prioritise
the retail market to maximise availability and awareness of product and
service, and secondly, to drive towards integration with the NHS to maximise
the benefits of ownership and accessibility of personal health data, whilst
aligning with the NHS 10-year plan for a unified patient health record. Our
partnership with PKB has taken us further towards this second goal of data
accessibility, and has strengthened our position as a trusted partner in
customers' healthcare journeys, enabling us to work with Boots and PKB to
drive as much uptake as possible by highlighting the options to upload their
test results via PKB to the NHS app, which has achieved tens of millions of
downloads since launch.
PocDoc
The launch of PocDoc by Vital Signs Solutions Limited earlier this year has
further paved the way for greater patient accessibility and control over their
critical health markers. With the Heart Health cholesterol test now launched,
we are gearing up for future product launches of the connected self-tests,
which are used within the NHS in selected health trusts. MHC is the exclusive
supplier of this product into Boots, which was added to the boots.com range in
April 2025 and launched in over 830 stores, alongside the Boots OB range, on 4
August 2025. We believe there is potential for PocDoc to achieve strong
growth off-the-shelf, as well as being part of a wider service offering, and
we will continue to drive through opportunities to enhance revenue growth of
this innovative, cost effective, and simple to use self-test.
Other Developments
Alongside our delivery on specific commercial projects, we have continued to
evolve our propriety digital platform to maximise scalability and resilience,
and we have upgraded our infrastructure to simplify future integrations with
third parties as and when they are required. We have also introduced automated
testing which accelerates the introduction of new features and enhancements,
improves quality control, and minimises the risk of errors. Our investment
continues to strengthen the delivery of a consistently reliable and trusted
customer experience.
Cyber security controls and data and information security management are also
high up on the team's agenda day to day, and in the past two years we have
achieved Cyber Essentials Plus and ISO 27001 accreditations, which we
successfully transitioned to the new ISO 27001:2022 in April 2025.
Financial performance
Sales for the six months ended 30 June 2025 amounted to £0.5m (six months
ended 30 June 2024: £0.9m; year ended 31 December 2024: £3.6m) with sales of
the wellness portfolio increasing by approximately 60% over the comparable
period in the prior year. This is a growing market, with rising demand, driven
in part by increased in-store shelf space and retailer endorsement, which is
improving customer awareness and understanding of the benefits of at-home
wellness testing.
Gross margin for the six months ended 30 June 2025 amounted to a loss of
£272,000 (six months ended 30 June 2024: £286,000) primarily due to the
impact of the relatively fixed direct cost base associated with the range of
wellness tests as well as reduced COVID revenue in the period under review.
Excluding the impact of movements in provisions and indirect fixed costs
included in cost of sales, the actual margin achieved on sales in the period
was 31% (six months ended 30 June 2024: 17%; year ended 31 December 2024: 23%)
which reflects the change in product mix as the lower margin COVID revenue has
decreased. Overall gross margin is expected to improve as the sales volumes of
the wellness product range increases to cover the fixed cost base.
Total spend on the development and maintenance of IT infrastructure during the
year to date amounted to £218,000 (six months ended 30 June 2024: £193,000;
year ended 31 December 2024: £377,000) of which £40,000 has been capitalised
(six months ended 30 June 2024: £47,000; year ended 31 December 2024:
£72,000). This investment has been in relation to the integration with PKB,
Boots OB improvements, and further ongoing improvements highlighted within the
Business Review.
Other overheads were broadly in line with the prior year due to the continued
focus on tight cost control. Sales and marketing costs increased from
£272,000 to £317,000 during the period under review to support retail
promotional activity and drive other initiatives to raise awareness of the
value proposition and to drive growth in sales of wellness products.
Adjusted EBITDA is calculated as follows:
Unaudited Unaudited Audited
30 June 2025 30 June 2024 31 December 2024
£'000 £'000 £'000
Operating loss (1,438) (1,348) (2,230)
Depreciation, amortisation and (profit)/loss on disposal 127 119 249
Termination costs 66 - -
Share based payments 15 30 54
Adjusted EBITDA (1,230) (1,199) (1,927)
As previously reported, the Company submitted a claim to HMRC for the
repayment of VAT levied on certain COVID PCR tests sold in earlier years. As
certain elements of the claim have been accepted exceptional income of
£206,000 was recognised during the year ended 31 December 2024. Since the
period end HMRC have also advised the Company that the sales of COVID PCR
tests made on a B2B basis should also be treated as exempt. However,
discussions with HMRC are still continuing around the net value of the claim
and the Company will provide an update on the outcome when the matter is fully
concluded.
At 30 June 2025 our cash amounted to £5,058,000 (six months ended 30 June
2024: £6,048,000; year ended 31 December 2024: £5,473,000).
Current trading and outlook
As a Board we believe in the positive long-term growth potential for our
wellness product range, but acknowledge that the category is still in its
infancy and that awareness amongst potential end-users is currently limited.
As an organisation with deep retail product knowledge, we have built a number
of partnerships to support our retail engagement in the home-testing market.
In particular, with Boots we are working with a trusted established retail
organisation, with both digital reach and a bricks and mortar footprint, and
we believe this is key to unlocking revenue potential in the UK market. With
several promotional campaigns being launched by Boots in the coming months we
expect to see demand increase as the range beds in, and increased product
visibility as more shelf space is dedicated to the range in store. This, along
with our other commercial partnerships, gives us confidence that we will
continue to deliver year-on-year growth in end-user sales for our Wellness
portfolio.
As always, I would like to thank our investors for their continued loyalty and
support, and our talented executive team and valued external partners who have
consistently developed excellence as we strive to secure a valuable place in
the future of accessible, preventative wellness.
Adam
Reynolds
Penny McCormick
Chairman
Chief Executive Officer
25 September 2025
Consolidated statement of comprehensive income
For the 6 months ended 30 June 2025
Unaudited Audited
6 months ended Unaudited Year ended
30 June 6 months ended 31 December 2024
2025 30 June
2024
Notes £'000 £'000 £'000
Revenue 3 494 881 3,607
Cost of sales (766) (1,167) (3,801)
Gross loss (272) (286) (194)
Sales and marketing costs (317) (272) (627)
Other administrative expenses (768) (760) (1,355)
Termination costs (66) - -
Share based payments (15) (30) (54)
Administrative expenses (849) (790) (1,409)
Operating loss (1,438) (1,348) (2,230)
Exceptional Income - - 206
Finance income 82 150 239
Finance expense - (1) (1)
Loss before and after income tax 3 (1,356) (1,199) (1,786)
Attributable to owners of the parent: (1,356) (1,199) (1,786)
Loss per Ordinary Share - basic 4
(2.62)p (2.31)p (3.45)p
Fully diluted earnings per Ordinary Share 4 (2.62)p (2.31)p (3.45)p
( )
Consolidated statement of financial position
As at 30 June 2025
Unaudited Unaudited Audited
30 June 2025 30 June 2024 31 December 2024
£'000 £'000 £'000
Non-current assets
Property, plant and equipment 52 66 82
Right-of-use assets - 37 -
Intangible assets 1,296 1,420 1,353
Total non-current assets 1,348 1,523 1,435
Current assets
Inventories 100 339 133
Trade and other receivables 1,909 161 1,761
Cash and cash equivalents 5,058 6,048 5,473
Total current assets 7,067 6,548 7,367
Total assets 8,415 8,071 8,802
Current liabilities
Trade and other payables 2,781 524 1,827
Lease liabilities - 12 -
Total liabilities 2,781 536 1,827
Net assets 5,634 7,535 6,975
Share capital 781 780 781
Share premium 3 - 3
Employee Benefit Trust (25) (25) (25)
Reverse acquisition reserve (6,044) (6,044) (6,044)
Retained earnings 10,919 12,824 12,260
Total equity 5,634 7,535 6,975
Consolidated statement of changes in equity
For the 6 months ended 30 June 2025
Share capital Share Premium Reverse acquisition Retained earnings Total
reserve
Employee
Benefit Trust
reserve
£'000 £'000 £'000 £'000 £'000 £'000
Equity as at 780 - (6,044) 13,993 8,704
1 January 2024 (25)
Loss for the year - - - (1,786) (1,786)
-
Total - - - (1,786) (1,786)
comprehensive loss -
Exercise of share 1 3 - (1) 3
options -
Share-based payments - - - 54 54
-
Equity as at 781 3 (6,044) 12,260 6,975
31 December 2024 (25)
Loss for the period - - - (1,356) (1,356)
-
Total - - - (1,356) (1,356)
comprehensive loss -
Share-based payments - - - 15 15
-
Equity as at 781 3 (6,044) 10,919 5,634
30 June 2025 (25)
Consolidated statement of cash flows
For the 6 months ended 30 June 2025
Unaudited Audited
6 months ended Unaudited Year ended
30 June 6 months ended 31 December 2024
2025 30 June
2024
£'000 £'000 £'000
Cash flows from operating activities
Loss before taxation (1,356) (1,199) (1,786)
Adjustments for:
Depreciation and amortization 127 124 255
Profit on sale of assets - (5) (6)
Finance income (82) (150) (239)
Finance expenses - 1 1
Share-based payments 15 30 54
Adjusted operating loss before changes in (1,296) (1,199) (1,721)
working capital
Changes in working capital
Decrease in inventory 33 3 209
(Increase)/decrease in trade and other receivables (148) 3,499 1,907
Increase/(decrease) in trade and other payables 954 (4,088) (2,785)
Cash used in operations (457) (1,785) (2,390)
Bank interest received 82 149 230
Net cash outflow from operating activities (375) (1,636) (2,160)
Investing activities
Proceeds from sale of fixed assets - 10 10
Purchase of office equipment - (14) (31)
Purchase of intangible assets (40) (47) (72)
Net cash flows used in investing activities (40) (51) (93)
Financing activities
Exercise of share options - - 3
Repayment of lease liability - (14) (26)
Cash outflows from financing activities - (14) (23)
Net change in cash and cash equivalents (415) (1,701) (2,276)
Cash and cash equivalents at the beginning of the period 5,473 7,749 7,749
Cash and cash equivalents at the end of the period 5,058 6,048 5,473
Notes to the unaudited interim financial information for the 6 months ended 30
June 2025
1. General information
MyHealthChecked PLC (the "Group") is a public limited company incorporated and
domiciled in England and Wales. The registered office of the Company is The
Maltings, East Tyndall Street, Cardiff, CF24 5EA. The registered company
number is 06573154.
The principal activity of the Group is in the development and
commercialisation of diagnostic healthcare products.
2. Significant accounting policies
Basis of preparation
The interim financial information for the six months ended 30 June 2025, which
was approved by the Board of Directors on 25 September 2025, does not
constitute statutory accounts as defined by section 434 of the Companies Act
2006.
These interim consolidated financial statements have been prepared in
accordance with IAS 34 Interim Financial Reporting. They do not include all
disclosures that would otherwise be required in a complete set of financial
statements.
The financial information presented is unaudited and has been prepared using
the same accounting policies as those adopted in the financial statements for
the year ended 31 December 2024 and expected to be adopted in the financial
year ending 31 December 2025.
The interim financial information includes unaudited comparative figures for
the unaudited 6 months to 30 June 2024 and comparatives for the year ended 31
December 2024 that have been extracted from the audited financial statements
for that year. The financial statements for the year ended 31 December 2024
were reported on by the Company's auditors and delivered to the Registrar of
Companies. The report of the auditors was unqualified and did not contain an
adverse statement under section 498 (2) or (3) of the Companies Act 2006.
In the opinion of the Directors, the interim financial information for the
period presents fairly the financial position and the results from operations
and cash flows for the period.
Going concern
The interim financial statements have been prepared under the going concern
basis as the Directors have undertaken a review of the future financing
requirements of the ongoing operation of the Group and considers the Group is
able to meet its working capital requirements.
3. Segment information
In the opinion of the directors, the Group has one class of business, being
that of the provision of diagnostic healthcare products. All the segment
assets associated with the provision of diagnostic healthcare products are
located in the UK.
Unaudited Unaudited Audited
30 June 2025 30 June 2024 31 December 2024
£'000 £'000 £'000
COVID related products - 572 2,881
Other 494 309 726
Revenue from the provision of diagnostic healthcare products 494 881 3,607
Loss from the provision of diagnostic healthcare products (1,092) (1,073) (1,698)
Exceptional income - - 206
Corporate costs (346) (275) (532)
Net finance income 82 149 238
Group loss before tax (1,356) (1,199) (1,786)
Cash 5,058 6,048 5,473
Segment assets 3,295 1,961 3,289
Corporate assets 62 62 40
Total assets 8,415 8,071 8,802
Segment liabilities 2,675 475 1,751
Corporate liabilities 106 61 76
Total liabilities 2,781 536 1,827
4. Loss per Ordinary Share
Unaudited Unaudited Audited
30 June 2025 30 June 2024 31 December 2024
Basic and diluted loss per Ordinary Share
Loss for the period £1,356,000 £1,199,000 £1,786,000
Weighted average number of shares - basic 52,035,932 52,005,932 52,006,836
Less shares held by Employee Benefit Trust (weighted) (184,111) (184,111) (184,111)
Weighted average no of shares 51,851,821 51,821,821 51,822,725
Weighted average number of shares - fully diluted 51,851,821 51,821,821 51,822,725
Loss per share - basic 2.62p 2.31p 3.45p
Fully diluted loss per share 2.62p 2.31p 3.45p
Basic loss per share is calculated by dividing the loss attributable to equity
holders of the Company by the weighted average number of Ordinary Shares in
issue during the period. Due to the loss in the six-month period ended 30
June 2025 the effect of the share options was considered anti-dilutive.
This interim financial statement will be released in accordance with the AIM
Rules for Companies, and will be available shortly on the Company's website at
https://investors.myhealthchecked.com/.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR QELFLEKLLBBQRecent news on Myhealthchecked
See all newsREG - MyHealthChecked PLC - Proposed Sale of Concepta Diagnostics Limited
AnnouncementREG - MyHealthChecked PLC - Half-year Report
AnnouncementREG - MyHealthChecked PLC - Result of AGM
AnnouncementREG - MyHealthChecked PLC - Partnership agreement with Patients Know Best
AnnouncementREG - MyHealthChecked PLC - Supply agreement with Boots for own-branded tests
Announcement